Innovent Biologics Expands Access to Seven New Treatments in China Innovent Biologics announces the inclusion of seven innovative therapies in China's National Reimbursement Drug List, enhancing patient access to essential medications.

Innovent Biologics Expands Access to Seven New Treatments in China #China #Suzhou #Innovent_Biologics #SYCUME #TYVYT

Innovent's SYCUME® Receives Approval as China's First IGF-1R Antibody for Thyroid Eye Disease Innovent Biologics announces the approval of SYCUME®, China's first IGF-1R monoclonal antibody, for treating thyroid eye disease, marking a critical advancement in patient care.

Innovent's SYCUME® Receives Approval as China's First IGF-1R Antibody for Thyroid Eye Disease #China #Suzhou #Innovent #Thyroid_Eye_Disease #SYCUME